Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

2013 - CTS 2013 Congress


This page contains exclusive content for the member of the following sections: TTS, CTS

Plenary: Metabolic Nutrition and Regenerative Medicine

18.1 - Clinical Experience with Immunosuppressive Drugs

Presenter: Giuseppe, Remuzzi, Bergamo, Italy
Authors: Giuseppe Remuzzi

Organ transplantation has proven to be an effective therapeutic for a large variety of disease states, but the chronic immunosuppression required for allograft survival increases the risk for infection and neoplasia. In the past 50 years, a wealth of experimental data has accumulated relating to strategies to preserve function and prolong graft survival. These strategies operate by inducing peripheral or central tolerance to the allograft, with protocols based on regulatory T cell induction as the most promising ones. However, as these protocols move into the clinic, there is recognition that little is known as to their efficacy when confronted with the human immune system: pre-existing memory T cells and 'heterologous immunity' in Ag-experienced humans but not in immunologically naive rodents, infections and early activation of innate immune response and the related inflammation-induced cytokine milieu that inhibit Treg activity while augmenting the T effector response, all pose significant barriers to tolerance induction.

A better understanding of cellular and molecular mechanisms by which memory T cells and innate immunity modulate transplantation tolerance and detailed immunological studies of the rare 'spontaneous tolerant' patients may lead to development of combined strategies that target and modulate the immune system at multiple levels.

Since the first successful renal transplantation in Boston in 1954, more than a million such procedures have been performed worldwide. By strikingly minimizing the incidence of acute rejection, immunosuppressive drugs have led to overall improvements in allograft and patient survivals. However, the improved short-term survival rates have come at a cost: these drugs generally need to be given for the entire life, induce many indirect and direct side-effects and pose an increased risk of life-threatening complications, infections and malignancies. Furthermore these therapies have had little effect on the inexorable loss of transplanted organs because of chronic allograft rejection.

Recent trends in long-term survival rates have indicated a progressive improvement of renal allograft half-lives, but this has been only observed in patients who never had an acute rejection episode. These data emphasize the critical role of the recipient’s alloimmune response as a major determinant of transplant outcome and highlight the need to develop novel strategies to induce immunologic donor-specific tolerance defined as a lack of a destructive immune response towards the graft in the presence of generalized immune competence. Ideally, tolerance should also translate into a lack of chronic rejection and late graft loss.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
This email address is being protected from spambots. You need JavaScript enabled to view it.

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada